Independent Pharmacy Roll-Up — Acquisition Thesis
Buy-and-build consolidation of independent community pharmacies, sourced via a proprietary AI screening engine I built.
Pursue a buy-and-build roll-up of independent community pharmacies — using proprietary AI screening to acquire owner-operated stores off-market at low-single-digit EBITDA multiples, integrate them onto a shared purchasing and clinical platform, and exit a scaled regional operator at a higher multiple. A focused ~25–35-store platform is achievable in 4–5 years; the edge is proprietary deal flow, not capital. Illustrative base case: ~3.0× MOIC / ~28% IRR.
~19,000 independent community pharmacies (NCPA 2025) generate ~$103B in annual revenue — a fragmented, owner-operated market consolidating at more than one closure a day. Owners are operators, not financial sellers, so processes are uncompetitive and pricing is negotiable. Fragmentation plus a retirement wave is the classic roll-up setup.
My platform scores a ~65k-record universe of non-chain pharmacies on a 6-factor model. I rejected normalization methods that inflated the target list to 25k–50k stores and kept a deliberately conservative score — isolating just 820 high-conviction targets, with the top 100 holding 83–85% stable under ±10% stress. The discipline is the moat: a short, vetted, off-market pipeline.
The 820 targets share a clear signature versus the field: 86% show stale licensing records (a retirement / disengagement proxy), sit in far less competitive markets (2.6 vs 14.9 pharmacies per 10k residents), and serve higher-income ZIPs ($98k vs $66k median). Profitable, defensible stores whose owners are most likely to sell.
Two cross-checks: a file buy at ~$3–5 per annual script (defensible off-market; chains pay $5–12+ in competitive deals), or a whole-business buy at ~2.5–4.0× EBITDA plus inventory. Independents run ~22% gross margin (NCPA), so we underwrite thin entry margins with room to expand. Base entry: blended ~3.5× EBITDA.
Illustrative Returns
| Scenario | Stores | EBITDA % | Exit | MOIC | IRR |
|---|---|---|---|---|---|
| Downside | 25 | 5% | 7.0× | ~2.0× | ~17% |
| Base | 30 | 6% | 7.5× | ~3.0× | ~28% |
| Upside | 35 | 6.5% | 8.0× | ~4.0× | ~38% |
Return driver: multiple arbitrage (buy ~3.5×, exit ~7–8× as a scaled platform) plus margin expansion. Pace check — 820 scored targets × ~6% win rate ≈ 49 reachable; a 30-store build implies a disciplined, not heroic, close rate.
Value-Creation Plan
- Purchasing scale — GPO / wholesaler improvements on a ~78% COGS base (~+150 bps)
- Reimbursement discipline — centralized PBM contracts and DIR-fee management (~+100 bps)
- Central fill & shared back office — ~$50–80k saved per store
- Net target — lift entry EBITDA from ~4% toward ~6% of revenue (+200–300 bps vs standalone)
Key Risks & Mitigants
- PBM & DIR pressure (CMS 2024 reforms; state PBM-delinking laws) → diversify into cash-pay clinical services
- Generic deflation → purchasing scale plus a richer service mix
- Amazon / mail-order → focus on high-touch local and rural markets
- 340B is upside only, not core EBITDA — given the 2024 appellate ruling on manufacturer restrictions and HRSA's 2026 rebate-model pilot
- Integration & pharmacist retention → earnouts, retention packages, phased onboarding (base case assumes modest post-close attrition)
Assumptions & Limitations
Illustrative case study — not a live deal or a forecast. Market context from the NCPA 2024–2025 Digest, CMS, and Drug Channels; valuation and return assumptions reflect 2024–2026 comparables and are clearly bounded. Target counts and screening signals are outputs of my proprietary, un-audited model. Returns are scenario estimates, highly sensitive to store count, margin capture, and exit multiple.